IMMUNOLOGY AND IMMUNOTHERAPY

$0P30FY2001CANIH

University Of Colorado Denver, Aurora CO

Investigators

Linked publications, trials & patents

Paper 39763739 Paper 39737640 Paper 39726772 Paper 39711559 Paper 39711135 Paper 39684443 Paper 39677775 Paper 39677720 Paper 39677022 Paper 39671500 Paper 39671496 Paper 39630148 Paper 39609428 Paper 39604567 Paper 39603869 Paper 39574899 Paper 39564580 Paper 39554114 Paper 39436696 Paper 39400608 Paper 39384405 Paper 39342284 Paper 39321266 Paper 39311710 Paper 39282307 Paper 39266537 Paper 39264810 Paper 39215796 Paper 39201277 Paper 39191549 Paper 39147413 Paper 39139560 Paper 39136655 Paper 39120971 Paper 39091762 Trial NCT05073848 Trial NCT05053737 Trial NCT05006040 Trial NCT04993859 Trial NCT04988490 Trial NCT04973007 Trial NCT04963283 Trial NCT04940468 Trial NCT04925193 Trial NCT04922112 Trial NCT04916990 Trial NCT04882111 Trial NCT04866758 Trial NCT04863092 Trial NCT04634110 Trial NCT04611022 Trial NCT04565457 Trial NCT04558138 Trial NCT04544592 Trial NCT04541407 Trial NCT04535102 Trial NCT04520867 Trial NCT04486573 Trial NCT04471363 Trial NCT04408092 Trial NCT04305366 Trial NCT04300478 Trial NCT04294693 Trial NCT04208243 Trial NCT04092803 Trial NCT04091867 Trial NCT04066218 Trial NCT04042935 Trial NCT04035408 Trial NCT04028167 Trial NCT04028063 Trial NCT04001101 Trial NCT03995082 Trial NCT03976193 Trial NCT03970226 Trial NCT03958565 Trial NCT03900793 Trial NCT03891654 Trial NCT03881098 Trial NCT03781154 Trial NCT03734653 Trial NCT03617679 Trial NCT03325634 Trial NCT01886859 Trial NCT01426334 Trial NCT01232829 Trial NCT00778167 Patent 9434994 Patent 8734778 Patent 8715649 Patent 8343502 Patent 8337830 Patent 8221763 Patent 8153136 Patent 8067559 Patent 7910315 Patent 7595060 Patent 7563447 Patent 7465454 Patent 7083787

Abstract

Description: (Applicant's Description) The overall goal of the Program in Immunology and Immunotherapy is to understand the basic elements of immunity and the mechanisms by which cancer cells evade the immune system so that new intervention strategies can be developed to reduce the cancer burden. This is accomplished programmatically by fostering collaborations and encouraging a broad range of investigations into the connections between immunity and cancer. The University of Colorado Cancer Center leadership reorganized the structure of the Cancer Center in 1998 and 1999 in order to better promote translational research and collaborations, and to strengthen the cancer focus. The old Melanoma and Neuro-oncology focus groups from Adult Clinical Oncology were combined with the Immunology Program to form the new Immunology and Immunotherapy Program. As a consequence, the Program in Immunology and Immunotherapy now has 35 full members holding primary appointments in the Departments of Cell and Structural Biology, Dermatology, Immunology, Medicine, Neurology, Pathology, Pediatrics, Radiology, Radiation Oncology, and Surgery. The group includes the Chair of the Department of Immunology and three members of the National Academy of Sciences. Program members have nearly $12 million in annual direct costs from more than ninety grants. Since the last review, there has been an increase in grants from all agencies, especially the NCI, and NIH. Program members contributed 250 publications, approximately 40 percent involving collaborations with two or more Cancer Center members as authors. Program project initiatives in bone marrow transplantation, melanoma therapy, and control of cell death and differentiation were undertaken. Recruitment of new faculty with interests in human tumor immunology and immunotherapy has been initiated. The Cancer Center provided seed funding to support pilot projects that might evolve into a program project application. Clinical trials in breast, brain, and skin cancer immunotherapy are underway, and promising pre-clinical studies on lung cancer treatment have been made.

View original record on NIH RePORTER →